Notice of the date of Zealand's Annual General Meeting 2017 and of deadline for proposals for the agenda

Investor News - No.1/2017

Notice of the date of Zealand's Annual General Meeting 2017 and of deadline for proposals for the agenda

Copenhagen, February 7, 2017 - Zealand hereby gives notice that its Annual General Meeting 2017 will be held on:

Wednesday April 5, 2017, at 3 p.m.
at
Plesner Law Firm
Amerika Plads 37
2100 Copenhagen Ø, Denmark

Deadline for submitting proposals for the agenda
The deadline for submitting proposals to be included on the agenda for the Annual General Meeting is February 21, 2017. Proposals may be sent by email to [email protected] or by letter to Zealand Pharma A/S, Smedeland 36, 2600 Glostrup, Denmark, att.: Investor Relations.

The notice convening the Annual General Meeting will be sent only by email
Notices convening Zealand's general meetings will be sent directly to shareholders by email. All Zealand shareholders can register an email address via the Shareholder Portal on the company's website.

Shareholders who would still like to receive notices convening general meetings by letter are kindly asked to register for this on the Shareholder Portal before March 1, 2017.

For further information, please contact:

Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, email: [email protected]

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates that primarily target specialty diseases with significant unmet needs.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin(TM) in the US and Lyxumia^® in the rest of the world. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus^®) and is marketed as Soliqua(TM) 100/33 in the US and has been approved as Suliqua(TM) in Europe.

Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (phase II); glepaglutide* (ZP1848) for short bowel syndrome (phase II); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (phase II) and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/dd1083bf-691f-477e-820f-3ce2c5b2dff0